The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients
Open accessAbstract
The efficacy of voriconazole in 107 patients with scedosporiosis was analyzed. Principal infection sites were the lungs/sinuses (24%), central nervous system (CNS) (20%), and bone (18%), while 21% of patients had disseminated infection. Solid organ transplantation (22%), hematological malignancy (21%), and surgery/trauma (15%) were the predominant underlying conditions. A successful therapeutic response was achieved in 57% of patients (median, 103 therapy days), with >98% of those responding receiving ≥28 days of therapy. Patients receiving primary therapy showed a 61% response versus 56% for the others. The best therapeutic responses were seen for skin/subcutaneous (91%) or bone (79%) infections, and the lowest for CNS infections (43%). Patients without major immune suppression (72%) or those with solid organ transplantation (63%) or various hematological conditions (60%) showed the best responses by underlying condition. Median known survival time was 133 days (therapy successes, 252 days; failures, 21 days). In all, 43 (40%) patients died, 73% due to scedosporiosis. Patients with Scedosporium prolificans infection had significantly reduced survival times ( P = 0.0259) and were more likely to die from fungal infection ( P = 0.002) than were Scedosporium apiospermum -infected patients. In a subset of 43 patients where voriconazole baseline MICs were available, response to voriconazole was higher for S. apiospermum -infected patients (54% response; MIC 50 , 0.25 μg/ml) than for S. prolificans -infected patients (40% response; MIC 50 , 4.0 μg/ml). Voriconazole demonstrated clinically useful activity in the treatment of both S. apiospermum and S. prolificans infections and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
(2016) · Lung Transplantation · doi:10.3109/9781439802571-25 · Cited by 2,157
de Hoog, S., Guarro, J., Gené, J., & Figueras, M. J. (2000) · UvA-DARE (University of Amsterdam) · Cited by 1,427
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
Self-citationMaertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., & Kleinermans, D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2546-2553.2002 · Cited by 415
Husain, S., Munoz, P., Forrest, G., Alexander, B. D., Somani, J., Brennan, K., Wagener, M. M., & Singh, N. (2005) · Clinical Infectious Diseases · doi:10.1086/426445 · Cited by 401
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN
Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N. R., Smith, D. A., Walker, D. K., & Wood, N. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.731 · Cited by 330
Hariprasad, S. M. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.1.42 · Cited by 312
Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*
Guarro, J., Kantarcioglu, A. S., Horré, R., Luis Rodriguez-Tudela, J., Cuenca Estrella, M., Berenguer, J., & Sybren De Hoog, G. (2006) · Medical Mycology · doi:10.1080/13693780600752507 · Cited by 297
Lutsar, I., Roffey, S., & Troke, P. (2003) · Clinical Infectious Diseases · doi:10.1086/377131 · Cited by 262
Self-citationIn Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates
Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., Rodriquez-Tudela, J. L., Donnelly, J. P., Verweij, P. E., & the EUROFUNG Network (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.62-68.2002 · Cited by 233
Nesky, M. A., McDougal, E. C., & Peacock, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/314042 · Cited by 214
Berenguer, J., Rodríguez-Tudela, J. L., Richard, C., Alvarez, M., Sanz, M. A., Gaztelurrutia, L., Ayats, J., & Martinez-Suarez, J. V. (1997) · Medicine · doi:10.1097/00005792-199707000-00004 · Cited by 213
Cuenca-Estrella, M., Ruiz-Díez, B., Martínez-Suárez, J. V., Monzón, A., & Rodríguez-Tudela, J. L. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.1.149 · Cited by 212
CASTIGLIONI, B., SUTTON, D. A., RINALDI, M. G., FUNG, J., & KUSNE, S. (2002) · Medicine · doi:10.1097/00005792-200209000-00001 · Cited by 211
Howden, B. P., Slavin, M. A., Schwarer, A. P., & Mijch, A. M. (2003) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-002-0877-z · Cited by 198
Self-citationEspinel-Ingroff, A., Chaturvedi, V., Fothergill, A., & Rinaldi, M. G. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3776-3781.2002 · Cited by 167
Scedosporium Infection in a Tertiary Care Cancer Center: A Review of 25 Cases from 1989-2006
Lamaris, G. A., Chamilos, G., Lewis, R. E., Safdar, A., Raad, I. I., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/509579 · Cited by 163
Voriconazole for Invasive Bone Aspergillosis: A Worldwide Experience of 20 Cases
Mouas, H., Lutsar, I., Dupont, B., Fain, O., Herbrecht, R., Lescure, F.-X., Lortholary, O., & The Voriconazole/Bone Invasive Aspergillosis Study Group (2005) · Clinical Infectious Diseases · doi:10.1086/428734 · Cited by 129
Self-citationJabado, N., Casanova, J., Haddad, É., Dulieu, F., Fournet, J., Dupont, B., Fischer, A., Hennequin, C., & Blanche, S. (1998) · Clinical Infectious Diseases · doi:10.1086/515015 · Cited by 128
Use of Voriconazole in Treatment of Scedosporium apiospermum Infection: Case Report
Girmenia, C., Luzi, G., Monaco, M., & Martino, P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.5.1436-1438.1998 · Cited by 123
Disseminated Infection and Colonization by Scedosporium prolificans: A Review of 18 Cases, 1990-1999
Idígoras, P., Pérez‐Trallero, E., Piñeiro, L., Larruskain, J., López-Lopategui, M. C., Rodríguez, N., & Gonzalez, J. M. (2001) · Clinical Infectious Diseases · doi:10.1086/320521 · Cited by 119
Symoens, F., Knoop, C., Schrooyen, M., Denis, O., Estenne, M., NOLARD, N., & Jacobs, F. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2005.12.011 · Cited by 113
Steinbach, W. J., Schell, W. A., Miller, J. L., & Perfect, J. R. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3981-3985.2003 · Cited by 105
Bhat, S. V., Paterson, D. L., Rinaldi, M. G., & Veldkamp, P. J. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600786564 · Cited by 100
Espinel-Ingroff, A. V., Johnson, E. M., Hockey, H. P., & Troke, P. F. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm518 · Cited by 99
Self-citationGosbell, I. B., Toumasatos, V., Yong, J., Kuo, R.-S., Ellis, D., & Perrie, R. C. (2003) · Mycoses (Berlin) · doi:10.1046/j.1439-0507.2003.00878.x · Cited by 85
Self-citationMaertens, J. A., Lagrou, K., Deweerdt, H., et al. (2000) · Annals of Hematology · doi:10.1007/s002779900137 · Cited by 85
Meningitis Caused by Pseudallescheria boydii Treated with Voriconazole
Poza, G., Montoya, J. G., Redondo, C., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313817 · Cited by 82
Nulens, E., Eggink, C. A., Rijs, A. J. M. M., Wesseling, P., & Verweij, P. E. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.5.2261-2264.2003 · Cited by 68
Scedosporium Species Infections and Treatments
Steinbach, W., & Perfect, J. (2003) · Journal of chemotherapy · doi:10.1179/joc.2003.15.supplement-2.16 · Cited by 64
Mursch, K., Trnovec, S., Ratz, H., Hammer, D., Horré, R., Klinghammer, A., de Hoog, S., & Behnke‐Mursch, J. (2005) · Child s Nervous System · doi:10.1007/s00381-005-1151-3 · Cited by 58
Efficacyof Voriconazole in Treatment of Systemic Scedosporiosis inNeutropenicMice
Capilla, J., Serena, C., Pastor, F. J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3976-3978.2003 · Cited by 58
Li, J. Y. Z., Yong, T. Y., Grove, D. I., & Coates, P. T. (2007) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2007.00240.x · Cited by 50
Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole
Porte, L., Khatibi, S., Hajj, L. E., Cassaing, S., Berry, A., Massip, P., Linas, M. D., Magnaval, J., Sans, N., & Marchou, B. (2006) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2005.12.010 · Cited by 48
Whyte, M., Irving, H., O’Regan, P., Nissen, M. D., Siebert, D. J., & Labrom, R. D. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000157213.94392.30 · Cited by 33
Capilla, J., & Guarro, J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.4009-4011.2004 · Cited by 33
Kanafani, Z. A., Comair, Y. G., & Kanj, S. S. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1233-2 · Cited by 33
Treatment of a chronic Scedosporium apiospermum vertebral osteomyelitis
German, J. W., Kellie, S. M., Pai, M. P., & Turner, P. T. (2004) · Neurosurgical FOCUS · doi:10.3171/foc.2004.17.6.9 · Cited by 28
Scedosporium/Pseudallescheria Infections
Panackal, A. A., & Marr, K. (2004) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2004-824901
Cited by
Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E., Meletiadis, J., Pana, Z.-D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 523
Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J.-H., Engelhard, D., Hope, W., Roilides, E., Styczynski, J., Warris, A., & Lehrnbecher, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70017-8 · Cited by 407
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Emerging fungal infections in immunocompromised patients
Low, C.-Y., & Rotstein, C. (2011) · F1000 Medicine Reports · doi:10.3410/m3-14 · Cited by 309
Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species
Lackner, M., de Hoog, G. S., Verweij, P. E., Najafzadeh, M. J., Curfs-Breuker, I., Klaassen, C. H., & Meis, J. F. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05910-11 · Cited by 290
Metadata
- Authors
- Troke, P., Aguirrebengoa, K., Arteaga, C., Ellis, D., Heath, C. H., Lutsar, I., Rovira, M., Nguyen, Q., Slavin, M., & Chen, S. C. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-05
- Volume
- 52
- Issue
- 5
- Pages
- 1743-1750
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2077919952
- Cited by
- 294
- References
- 45
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.